Clearside Biomedical gets $20M for drug-device combo for blindness disorders
Clearside Biomedical will use the Series C round to further clinical trials for its drug-device combination for diseases of the eye that cause blindness.
Ophthalmology startup uses microneedles for targeted delivery of drugs for retinal diseases
A one-year-old company using drug delivery to improve ophthalmic drugs is raising fresh capital to support trials of its microinjection platform. Clearside Biomedical has raised $7.9 million and could continue raising up to $8.5 million, according to a U.S. Securities and Exchange Commission filing made last week. The company is hoping to stave off retinal […]
presented by
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Clearside raises $4M for targeted drug delivery system and new eye drug
Ophthalmic startup Clearside Biomedical has launched with a $4 million initial round of investment for the company to continue R&D on its lead drug candidate and a novel drug delivery system that could administer that drug in hard to access regions of the eye. Clearside is headquartered in Atlanta but will maintain research operations in […]